My Blue Dots

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer and infectious diseases, today announced a clinical trial collaboration and supply agreement with Amgen (NASDAQ:AMGN) to evaluate etakafusp alfa (formerly known as AB248), Asher Bio’s investigational CD8+ T cell targeted interleukin-2 (IL-2) immunotherapy, in combination with IMDELLTRA® (tarlatamab), Amgen’s DLL3-targeting Bispecific T-cell Engage

SAN FRANCISCO–(BUSINESS WIRE)–Tonal, the pioneer of the world’s smartest strength training system, today unveiled Tonal 2, the latest iteration of its breakthrough at-home fitness solution. Updated from the inside out, Tonal 2 features an all-black design with sleek chrome accents that seamlessly complement any living space, along with hardware advancements and greater durability that level up the toughest workouts. Beyond its striking new look, Tonal 2 introduces cutting-edge workout feature

VANCOUVER, British Columbia–(BUSINESS WIRE)– #biotech–Aspect Biosystems secures $115M Series B to advance bioprinted tissue therapeutics, accelerating development of functional cures for serious diseases

AUSTIN, Texas–(BUSINESS WIRE)– #JPM2025–Gameto to Present at 43rd Annual J.P. Morgan Healthcare Conference

SAN DIEGO & BERLIN & DURHAM, N.C.–(BUSINESS WIRE)–Vividion Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets and develop small molecule precision therapeutics for devastating cancers and immune disorders, today announced the acquisition of Tavros Therapeutics, Inc., a precision oncology platform company. Vividion is a wholly owned and independently operating subsidiary of Bayer AG. The

NATICK, Mass.–(BUSINESS WIRE)–Allurion Technologies, Inc. (NYSE: ALUR), a company dedicated to ending obesity, today announced topline results from the AUDACITY Food & Drug Administration (FDA) pivotal trial evaluating the safety and efficacy of the Allurion Balloon. The AUDACITY trial is an open-label, multicenter, randomized, controlled study and is the first FDA pivotal trial on an intragastric balloon for weight loss to report primary outcomes beyond 9 months. 550 subjects were random

TORONTO–(BUSINESS WIRE)—- $ALGO #Cboe–Light AI Inc. is available for trading on the Cboe Canada exchange under the symbol ALGO.

CAMBRIDGE, Mass. & LAUSANNE, Switzerland–(BUSINESS WIRE)–Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced positive symptom data from its Phase 2 ACeD-it trial evaluating its lead candidate, KAN-101, in individuals with celiac disease. The study data serves as the first symptomatic clinical proof of concept for KAN-101 and its potential as a disease-modifying treatment for celiac disease. KAN-101 ind

SAN DIEGO–(BUSINESS WIRE)–Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the initiation of a Phase 2 clinical trial evaluating ABX-002, its highly potent, oral, thyroid hormone beta receptor (TRβ) selective agonist, as an adjunctive treatment in adults with bipolar depression. The Phase 2 trial aims to establish biological and clinical proof-of-concept for ABX-002 in bipol

DENVER–(BUSINESS WIRE)–TriSalus announces leadership changes.